WellPoint Clarinex Switch Petition Assertions Are “Troubling” – NCL
This article was originally published in The Tan Sheet
Executive Summary
An FDA-mandated OTC switch of Schering-Plough's Clarinex (desloratadine) would be "troubling" and would represent "a serious shift in agency policy," the National Consumers League states
You may also be interested in...
Clarinex Clinical, Safety Characteristics Support OTC Use – WellPoint
The similar safety and efficacy profile of Schering-Plough's follow-on drug Clarinex (desloratadine) to other second-generation antihistamines makes it appropriate for OTC availability, WellPoint Health Networks asserts in an April 15 petition to FDA
OTC Sale Of Rx Allergy Drugs Would Be Safer, Cut Costs - Health Plan
Nonsedating antihistamines classified as prescription drugs would be more appropriately sold as OTCs, Blue Cross of California Pharmacy VP Rob Seidman maintains in Jan. 12 letters sent to marketers of the drugs.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC